Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

SES cost effective in high-risk patients in Canada

    • 12 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Rinfret S, Cohen DJ, Tahami Monfared AA, Lelorier J, Mireault J, Schampaert E.Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial. American Journal of Cardiovascular Drugs 6: 159-168, No. 3, 2006

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    SES cost effective in high-risk patients in Canada. Pharmacoecon. Outcomes News 509, 4 (2006). https://doi.org/10.2165/00151234-200605090-00009

    Download citation

    Keywords

    • Percutaneous Coronary Intervention
    • Coronary Artery Bypass Graft
    • Coronary Artery Bypass Graft Surgery
    • Absolute Risk Reduction
    • Repeat Revascularisation